Combined therapy composition and combined therapy method for treating cancers

一种免疫治疗、靶向治疗剂的技术，应用在化学仪器和方法、药物组合、基因治疗等方向

Inactive Publication Date: 2016-01-13
BIRDIE BIOPHARM INC
View PDF56 Cites 26 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the strict technical requirements in terms of antibodies, linker molecules, toxin molecules, conjugation, and limited molecules that can bring toxins into the tumor microenvironment, there are still some difficulties in actual clinical research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined therapy composition and combined therapy method for treating cancers
  • Combined therapy composition and combined therapy method for treating cancers
  • Combined therapy composition and combined therapy method for treating cancers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0468] Enrichment of Human Dendritic Cells (DC) from PBMC

[0469] Human PBMCs were prepared from erythrocytes obtained from healthy voluntary donors by Ficoll centrifugation. Dendritic cells were enriched from magnetic beads (Miltenyi Biotec Inc. San Diego, CA) with a mixture of anti-CD3, anti-CD19, anti-CD20, anti-CD14 and anti-CD16 antibodies from human PBMCs by using negative subtraction. Enriched DCs were stained with goat anti-mouse FITC (lineage), HLA-DR-APCCy7, CD123-BV421 and CD11C-APC. Stained cells were analyzed on BDLSR Fortessa (BD Biosciences). Anti-CD3 mAb, anti-CD4 mAb, anti-CD11C mAb, anti-CD19 mAb, anti-CD14 mAb, anti-CD16 mAb, anti-CD123 mAb were purchased from BD Biosciences, CA or Biolegend, San Diego , CA.

[0470] Stimulation of enriched human DCs and expression of cytokines

[0471] Will be 1-2 x 10 5 Enriched DCs were seeded in 96-well plates in 100 μl of medium, 100 μl of diluted stimulators including BDs100 (resiquimod) were added to the pla...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a therapy composition and a therapy method for treating cancers by virtue of combined therapy.

Description

technical field [0001] The present invention relates to therapeutic combinations and methods for treating cancer using combination therapies. Background technique [0002] Therapeutic antibodies have been used in clinical applications for more than two decades. At present, fifteen kinds of anti-tumor antibody drugs have been used clinically, including: Rituxan (1997), Herceptin (1998), Mylotarg (2000), Campath (2001), Zevalin (2002) , Bexxer (2003), Avastin (2004), Erbitux (2004), Vectibix (2006); Arzerra (2009); Benlysta (2011); Yervoy (2011); Adcetris (2011); Perjeta (2012); and Kadcyla (2013 ). These antibodies primarily target four molecules: EGFR, Her2, CD20 and VEGF. [0003] In general, therapeutic antibodies kill tumor cells through three mechanisms (ScottAM, WolchokJD, OldLJ.Antibodytherapyofcancer.NatRevCancer.(2012), 12:278-87): (1) Antibody direct action, that is, blocking or activating ligand body / receptor signaling activity, induction of apoptosis and deliv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K48/00A61P35/00A61K39/395
CPCA61K45/06A61K31/138A61K31/337A61K31/366A61K31/4196A61K31/4535A61K31/475A61K31/506A61K31/555A61K31/5685A61K31/675A61K31/7068A61K39/39558C07K16/32A61K31/4745A61P35/00A61P43/00A61K2300/00A61K2039/505
Inventor 李立新
Owner BIRDIE BIOPHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap